Shortened Spadin Analogs Display Better TREK-1 Inhibition,

Shortened Spadin Analogs Display Better TREK-1 Inhibition,

Frontiers in pharmacology (2017-09-29)

Alaeddine Djillani, Mariel Pietri, Sébastien Moreno, Catherine Heurteaux, Jean Mazella, Marc Borsotto

摘要

Depression is a devastating mental disorder that affects 20% of the population worldwide. Despite their proven efficacy, antidepressants present a delayed onset of action and serious adverse effects. Seven years ago, we described spadin (PE 12-28) as a promising endogenous peptide with antidepressant activity. Spadin specifically blocks the TREK-1 channel. Previously, we showed